Analyst Price Targets — IMCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:17 pm | — | Mizuho Securities | $38.00 | $32.51 | TheFly | Immunocore price target raised to $38 from $37 at Mizuho |
| January 7, 2026 5:43 am | Michael Yee | UBS | $55.00 | $32.85 | StreetInsider | UBS Assumes Immunocore Holdings (IMCR) at Buy |
| November 10, 2025 5:15 pm | Sean Laaman | Morgan Stanley | $36.00 | $34.53 | TheFly | Immunocore price target raised to $36 from $34 at Morgan Stanley |
| October 31, 2025 10:16 am | Eva Fortea Verdejo | Wells Fargo | $60.00 | $32.19 | TheFly | Immunocore initiated with an Overweight at Wells Fargo |
| March 7, 2025 1:37 pm | — | Morgan Stanley | $35.00 | $29.80 | TheFly | Immunocore assumed with an Equal Weight at Morgan Stanley |
| October 24, 2024 3:51 am | David Dai | UBS | $24.00 | $32.02 | StreetInsider | UBS Starts Immunocore Holdings (IMCR) at Sell |
| September 16, 2024 10:00 am | Justin Kim | Oppenheimer | $89.00 | $33.05 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Immunocore Holdings (IMCR) |
| September 12, 2024 7:54 am | Graig Suvannavejh | Mizuho Securities | $72.00 | $33.44 | StreetInsider | Mizuho Reiterates Outperform Rating on Immunocore Holdings (IMCR) |
| August 28, 2024 6:41 am | Patrick Trucchio | H.C. Wainwright | $100.00 | $35.71 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Immunocore Holdings (IMCR) |
| August 9, 2024 5:23 am | Peter Lawson | Barclays | $66.00 | $37.92 | TheFly | Immunocore price target lowered to $66 from $92 at Barclays |
Latest News for IMCR
Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ: IMCR - Get Free Report) have earned an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eight have assigned a buy recommendation
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian…
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMCR.
U.S. House Trading
No House trades found for IMCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.